Dry Age-Related Macular Degeneration

Galimedix Therapeutics announced the initiation of its phase 2 eDREAM study to assess the safety and efficacy of GAL-101 eye drops in patients with dry age-related macular degeneration, according to a company press release.

CHICAGO —In this video, Karl G. Csaky, MD, PhD, highlights discussions from the AAO meeting on the adequacy of tools used to assess the effectiveness of treatments for dry age-related macular degeneration.

CHICAGO — In this video, Karl G. Csaky, MD, PhD, discusses highlights from the AAO annual meeting.

The FDA granted de novo marketing authorization Valeda Light Delivery System for the treatment of dry age-related macular degeneration, according to a press release from LumiThera.

BARCELONA, Spain — In this Healio Video Perspective from the ESCRS meeting, Federico Badalà, MD, shares his experience with the EyeMax Mono IOL in patients with insignificant cataract and dry age-related macular degeneration.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Reenie McCarthy of Stealth BioTherapeutics discusses a phase 3 clinical trial of elamipretide in dry age-related macular degeneration.

SEATTLE — A study on progression of dry age-related macular degeneration found that smoking did not affect the likelihood of developing wet AMD, but smokers had worse visual acuity than nonsmokers.

SEATTLE — Patients who develop certain subtypes of geographic atrophy may be at risk for a decline in health-related quality of life, according to research presented at the Association for Research in Vision and Ophthalmology meeting.